BCL2 and acute myeloid leukemia: The BETi ABBV-075 has been evaluated as a putative agent to overcome resistances to venetoclax-mediated BCL-2 inhibition in both AML cell lines as well as in models of AML blast progenitor cells (BPCs) engrafted in immune-compromised mice.